Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HINT1 | P49773 | 4/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL10811044 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL278157 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL12959061 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL7062800 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL973437 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795486-B2 | Enzymatic method for preparation of GDP-fucose | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-10-24 | — | — | US | disclosed |
| EP-3784792-B9 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023109801-A1 | SUPRAMOLECULAR HYDROGEL CAPABLE OF LIPOPHILIC DRUG DELIVERY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川大学 | 2023-06-22 | — | — | WO | disclosed |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230137773-A1 | RAS INHIBITORY PEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-05-04 | — | — | US | disclosed |
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | IMMUNESENSOR THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220218605-A1 | BIFUNCTIONAL NUCLEOSIDE HYDROGEL, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2022-07-14 | — | — | US | disclosed |
| US-11377476-B2 | Ras inhibitory peptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220177940-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-09 | — | — | US | disclosed |
| US-8173797-B2 | Sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine | CORNELL RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| EP-2298354-A2 | Remodelling and glycoconjugation of interferon-beta | BioGeneriX AG (DE) | 2011-03-23 | — | — | EP | disclosed |
| EP-2279753-A2 | Remodeling and glycoconjugation of peptides | Novo Nordisk A/S (DK) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009116044-A2 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-24 | — | — | WO | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193452-A1 | Therapeutic Compounds Derived from Spider Venom and Their Method of Use | ADAR, FUT5, CSGALNACT1 | HPGD 2467/4885HINT1 920/4885NT5E 47/4885 |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | HPGD 1662/4885HINT1 376/4885NT5E 37/4885 |
| US-20230137773-A1 | RAS INHIBITORY PEPTIDES AND USES THEREOF | TPX2, RASGRP1, KRAS | HPGD 3787/4885HINT1 2945/4885NT5E 2226/4885 |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | HPGD 381/4885HINT1 179/4885NT5E 24/4885 |
| US-20220340613-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | CGAS, PDE7A, PDE11A | HPGD 201/4885HINT1 423/4885NT5E 77/4885 |
| US-20110086813-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | REL, RELA, NFKB1 | HPGD 1143/4885HINT1 741/4885NT5E 492/4885 |
| US-20220218605-A1 | BIFUNCTIONAL NUCLEOSIDE HYDROGEL, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, OGG1 | HPGD 165/4885HINT1 86/4885NT5E 577/4885 |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | HPGD 2125/4885HINT1 2052/4885NT5E 944/4885 |
| US-11377476-B2 | Ras inhibitory peptides and uses thereof | KRAS, RASGRP1, RASGRP3 | HPGD 3737/4885HINT1 2821/4885NT5E 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.